Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medco Adds 15-20 Specialty Pharmacy Products Under Accredo Deal

Executive Summary

Medco's 10-year agreement with Accredo Health will increase its specialty pharmacy offering by 15 to 20 products

You may also be interested in...



Medco Creates Largest U.S. Specialty Pharmacy Through Accredo Acquisition

Medco will become the largest specialty drug distributor in the U.S. through its proposed acquisition of Accredo, with combined sales of approximately $4.3 bil. in 2004

Medco Creates Largest U.S. Specialty Pharmacy Through Accredo Acquisition

Medco will become the largest specialty drug distributor in the U.S. through its proposed acquisition of Accredo, with combined sales of approximately $4.3 bil. in 2004

Medco Hopes For Greater Strategic Freedom, Lower Litigation Risk By 2006

The second anniversary of Medco's spin-off from Merck will give the pharmacy benefit management company additional flexibility to pursue strategic moves in anticipation of the Medicare prescription drug benefit

Related Content

UsernamePublicRestriction

Register

PS043348

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel